Psoriaatiline

Psoriaatiline is a fictional synthetic small-molecule investigated as a potential treatment for psoriasis and related inflammatory dermatoses. Described in pharmacology literature as an oral agent with immunomodulatory properties, it is proposed to act by dampening pathogenic T-cell responses and epidermal hyperproliferation characteristic of psoriatic lesions.

In proposed mechanism, Psoriaatiline inhibits signaling pathways such as NF-κB and MAPK, reducing production of cytokines including IL-17 and TNF-α in skin. Pharmacokinetic properties in preclinical models suggest moderate oral bioavailability, hepatic metabolism primarily by CYP enzymes, a terminal half-life in the range of several hours, and primary elimination via urine and feces.

Preclinical studies reported decreased keratinocyte proliferation and lesional inflammation in psoriatic mouse models. Early clinical trials in healthy volunteers indicated tolerability and a favorable safety profile. Phase II studies in patients with plaque psoriasis reported trend-level improvements in PASI scores, but results were not decisive, and development status remained exploratory.

Safety considerations identified in early studies included transient headache and mild gastrointestinal symptoms, with monitoring for infections and lipid profile changes recommended due to immunomodulatory effects. As of the latest available information, Psoriaatiline had not received regulatory approval and remained a compound in investigational literature or in preclinical discussion.